Investment Thesis
Neuphoria Therapeutics is a pre-revenue pharmaceutical company burning cash at an unsustainable rate (-$10.2M operating cash outflow) with negative margins across all profitability metrics (-62.1% operating margin, -51.4% net margin). While the balance sheet provides 2-3 years of runway and EPS improved 98.8% YoY, the company must demonstrate significant revenue acceleration and pathway to profitability to justify continued losses.
Strengths
- Fortress balance sheet with $22.2M cash, 0.0x debt/equity ratio, and minimal liabilities ($6.9M)
- Exceptional liquidity position with 9.04x current ratio provides substantial financial flexibility
- EPS improvement trend (+98.8% YoY) indicates operational losses are narrowing
Risks
- Severe cash burn (-$10.2M free cash flow) with only 2-3 years of runway at current burn rate despite strong cash reserves
- Deeply unprofitable operations with -$9.7M operating income on $15.6M revenue (-62.1% operating margin)
- Pre-commercial stage biotech with execution risk: no visible revenue growth trajectory, limited pipeline visibility, and high probability of dilutive capital raises needed
Key Metrics to Watch
- Operating cash flow trend and cash runway longevity relative to clinical trial progression
- Revenue growth acceleration and gross margins as products approach/enter commercialization
- Path to operating profitability and timeline to break-even or next major clinical milestone
Financial Metrics
Revenue
15.6M
Net Income
-8.0M
EPS (Diluted)
$-2.66
Free Cash Flow
-10.2M
Total Assets
36.6M
Cash
22.2M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-62.1%
Net Margin
-51.4%
ROE
-27.1%
ROA
-22.0%
FCF Margin
-65.4%
Balance Sheet & Liquidity
Current Ratio
9.04x
Quick Ratio
9.04x
Debt/Equity
0.00x
Debt/Assets
18.8%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-13T04:18:26.415797 |
Data as of: 2025-12-31 |
Powered by Claude AI